Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

90 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Natalizumab and progressive multifocal leukoencephalopathy.
Adelman B, Sandrock A, Panzara MA. Adelman B, et al. Among authors: sandrock a. N Engl J Med. 2005 Jul 28;353(4):432-3. doi: 10.1056/NEJMc055235. Epub 2005 Jun 9. N Engl J Med. 2005. PMID: 15947083 No abstract available.
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.
Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW; AFFIRM Investigators. Polman CH, et al. Among authors: sandrock aw. N Engl J Med. 2006 Mar 2;354(9):899-910. doi: 10.1056/NEJMoa044397. N Engl J Med. 2006. PMID: 16510744 Free article. Clinical Trial.
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, Lublin FD, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, Sandrock AW; SENTINEL Investigators. Rudick RA, et al. Among authors: sandrock aw. N Engl J Med. 2006 Mar 2;354(9):911-23. doi: 10.1056/NEJMoa044396. N Engl J Med. 2006. PMID: 16510745 Free article. Clinical Trial.
More on melanoma with transdifferentiation.
Panzara MA, Bozic C, Sandrock AW. Panzara MA, et al. Among authors: sandrock aw. N Engl J Med. 2008 Jul 3;359(1):99; author reply 99-100. doi: 10.1056/NEJMc086089. N Engl J Med. 2008. PMID: 18596284 No abstract available.
Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis.
Radue EW, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Rudick RA, Lublin FD, Weinstock-Guttman B, Wynn DR, Fisher E, Papadopoulou A, Lynn F, Panzara MA, Sandrock AW; SENTINEL Investigators. Radue EW, et al. Among authors: sandrock aw. J Neurol Sci. 2010 May 15;292(1-2):28-35. doi: 10.1016/j.jns.2010.02.012. Epub 2010 Mar 16. J Neurol Sci. 2010. PMID: 20236661 Clinical Trial.
Infusion-related hypersensitivity reactions during natalizumab treatment.
Phillips JT, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Polman CH, Lublin FD, Giovannoni G, Wajgt A, Lynn F, Panzara MA, Sandrock AW; AFFIRM Investigators. Phillips JT, et al. Among authors: sandrock aw. Neurology. 2006 Nov 14;67(9):1717-8. doi: 10.1212/01.wnl.0000242629.66372.33. Neurology. 2006. PMID: 17101921 Clinical Trial. No abstract available.
MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS.
Miller DH, Soon D, Fernando KT, MacManus DG, Barker GJ, Yousry TA, Fisher E, O'Connor PW, Phillips JT, Polman CH, Kappos L, Hutchinson M, Havrdova E, Lublin FD, Giovannoni G, Wajgt A, Rudick R, Lynn F, Panzara MA, Sandrock AW; AFFIRM Investigators. Miller DH, et al. Among authors: sandrock aw. Neurology. 2007 Apr 24;68(17):1390-401. doi: 10.1212/01.wnl.0000260064.77700.fd. Neurology. 2007. PMID: 17452584 Clinical Trial.
GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study.
Goodman AD, Rossman H, Bar-Or A, Miller A, Miller DH, Schmierer K, Lublin F, Khan O, Bormann NM, Yang M, Panzara MA, Sandrock AW; GLANCE Investigators. Goodman AD, et al. Among authors: sandrock aw. Neurology. 2009 Mar 3;72(9):806-12. doi: 10.1212/01.wnl.0000343880.13764.69. Neurology. 2009. PMID: 19255407 Free PMC article. Clinical Trial.
Assessing disability progression with the Multiple Sclerosis Functional Composite.
Rudick RA, Polman CH, Cohen JA, Walton MK, Miller AE, Confavreux C, Lublin FD, Hutchinson M, O'Connor PW, Schwid SR, Balcer LJ, Lynn F, Panzara MA, Sandrock AW. Rudick RA, et al. Among authors: sandrock aw. Mult Scler. 2009 Aug;15(8):984-97. doi: 10.1177/1352458509106212. Mult Scler. 2009. PMID: 19667023
90 results